Rating Change
Maxim Group reiterated its Buy rating on Health In Tech, Inc. (NASDAQ:HIT) on August 14, 2026.
Maxim Group reiterated its Buy rating on Health In Tech, Inc. (NASDAQ:HIT) on August 14, 2026.

At publication ·
Health In Tech, Inc. (NASDAQ:HIT) · reiterate
At a glance
Maxim Group reiterated its Buy rating on Health In Tech, Inc. (NASDAQ:HIT) on August 14, 2026.
Health In Tech, Inc. operates in the Technology sector. The stock currently trades at $1.00 with a market capitalization of $60.6M. The stock has declined 66.2% over the past 52 weeks.
Analyst coverage from Maxim Group provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Health In Tech, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 3 most recent ratings: 3 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | Maxim Group | Buy | N/A |
| Apr 20, 2026 | Craig-Hallum | Buy | N/A |
| Jun 26, 2025 | Maxim Group | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View HIT Stock Page
A rating of Buy from Maxim Group reflects the analyst's outlook on Health In Tech, Inc. (NASDAQ:HIT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the HIT forecast page.
Current market data
NASDAQ · HIT
$0.94
Up: +$0.01 · +0.57%
Live quote updated
Keep reading